Linked e-resources
Details
Table of Contents
Part I: Diagnosis of Pancreatic Cancer; 1: Early Diagnosis of Pancreatic Cancer Using Endoscopic Ultrasound; 1.1 Introduction; 1.2 EUS (Fig. 1.1); 1.3 Early Diagnosis of PC Using EUS; 1.4 Pancreatic Intraepithelial Neoplasia (PanIN); 1.5 Surveillance of High-Risk Individuals; 1.6 New Screening Modality Comprising Contrast EUS and Elastography; 1.7 Early Diagnosis of PC Using EUS-FNA (Fig. 1.3); References; 2: Evaluation of Resectability for Pancreatic Cancer Using Endoscopic Ultrasound; 2.1 Introduction; 2.2 EUS Diagnosis of Vascular Invasion in Pancreatic Cancer
2.3 EUS Diagnosis of Node Metastasis in Pancreatic Cancer2.4 EUS Diagnosis of Liver Metastases in Pancreatic Cancer; References; 3: Evaluation of Resectability of Pancreatic Cancer by MDCT; 3.1 Introduction; 3.2 Method of Contrast-Enhanced Dynamic MDCT for Pancreas; 3.3 Diagnosis of Extent of Spread of Pancreatic Cancer; 3.4 Final Remarks; References; 4: Evaluation of Effect of Neoadjuvant Therapy Using Positron Emission Tomography; 4.1 Introduction; 4.2 PET-CT: Diagnostic Efficacy in the Detection and Differential Diagnosis of Pancreatic Cancer; 4.2.1 Diagnostic Efficacy
4.2.2 Usefulness of PET for Selecting Initial Treatment4.3 Determining Prognosis According to PET-CT Parameters and Assessment of Metabolic Response by Neoadjuvant Treatment; 4.3.1 The Clinical Implications of SUV Values; 4.3.2 SUV Value After Neoadjuvant Therapy; 4.3.3 Volumetric and Other Parameters (GTV, MTV, TLG); 4.4 Current Research Gaps and Possible Future Work; References; 5: Liquid Biopsy for Early Detection of Pancreatic Cancer; 5.1 Implications of Early Diagnosis in Pancreatic Cancer; 5.2 Liquid Biopsy in Cancer; 5.2.1 Cell-Free DNA; 5.2.2 Origin of cfDNA
5.2.3 cfDNA as a Biomarker for Cancer5.2.4 Methods for Detection of ctDNA; 5.3 Liquid Biopsy in Pancreatic Cancer Diagnosis; 5.4 Challenges Facing Early Detection of Pancreatic Cancer by Liquid Biopsy; 5.5 Conclusions and Future Directions; References; Part II: Pancreaticoduodenectomy for Pancreatic Cancer: Indications and Procedure; 6: Standard Resection and Extended Resection; 6.1 Introduction; 6.2 Comparison Between Standard and Extended Resection; 6.2.1 Rationale for Dissection of Lymph Node and Nerve Plexus; 6.2.2 Extent of Pancreaticoduodenectomy
6.2.3 Results of Our Randomized Controlled Study6.2.4 Meta-Analyses on Optimal Extent of Resection; 6.3 Vascular Resection; References; 7: Pylorus-Resecting Pancreaticoduodenectomy; 7.1 Transition of Pancreaticoduodenectomy; 7.2 Procedure of PrPD; 7.3 Which Is Better, PD, PpPD, or PrPD?; 7.4 The Impact of Pylorus-Resecting Pancreaticoduodenectomy (PrPD); 7.5 Long-Term Outcomes in PrPD; References; 8: Pancreaticoduodenectomy with Portal Vein Resection; 8.1 Diagnostic Workup; 8.2 Classification of Venous Involvement; 8.3 Technical Aspects of Venous Resections
2.3 EUS Diagnosis of Node Metastasis in Pancreatic Cancer2.4 EUS Diagnosis of Liver Metastases in Pancreatic Cancer; References; 3: Evaluation of Resectability of Pancreatic Cancer by MDCT; 3.1 Introduction; 3.2 Method of Contrast-Enhanced Dynamic MDCT for Pancreas; 3.3 Diagnosis of Extent of Spread of Pancreatic Cancer; 3.4 Final Remarks; References; 4: Evaluation of Effect of Neoadjuvant Therapy Using Positron Emission Tomography; 4.1 Introduction; 4.2 PET-CT: Diagnostic Efficacy in the Detection and Differential Diagnosis of Pancreatic Cancer; 4.2.1 Diagnostic Efficacy
4.2.2 Usefulness of PET for Selecting Initial Treatment4.3 Determining Prognosis According to PET-CT Parameters and Assessment of Metabolic Response by Neoadjuvant Treatment; 4.3.1 The Clinical Implications of SUV Values; 4.3.2 SUV Value After Neoadjuvant Therapy; 4.3.3 Volumetric and Other Parameters (GTV, MTV, TLG); 4.4 Current Research Gaps and Possible Future Work; References; 5: Liquid Biopsy for Early Detection of Pancreatic Cancer; 5.1 Implications of Early Diagnosis in Pancreatic Cancer; 5.2 Liquid Biopsy in Cancer; 5.2.1 Cell-Free DNA; 5.2.2 Origin of cfDNA
5.2.3 cfDNA as a Biomarker for Cancer5.2.4 Methods for Detection of ctDNA; 5.3 Liquid Biopsy in Pancreatic Cancer Diagnosis; 5.4 Challenges Facing Early Detection of Pancreatic Cancer by Liquid Biopsy; 5.5 Conclusions and Future Directions; References; Part II: Pancreaticoduodenectomy for Pancreatic Cancer: Indications and Procedure; 6: Standard Resection and Extended Resection; 6.1 Introduction; 6.2 Comparison Between Standard and Extended Resection; 6.2.1 Rationale for Dissection of Lymph Node and Nerve Plexus; 6.2.2 Extent of Pancreaticoduodenectomy
6.2.3 Results of Our Randomized Controlled Study6.2.4 Meta-Analyses on Optimal Extent of Resection; 6.3 Vascular Resection; References; 7: Pylorus-Resecting Pancreaticoduodenectomy; 7.1 Transition of Pancreaticoduodenectomy; 7.2 Procedure of PrPD; 7.3 Which Is Better, PD, PpPD, or PrPD?; 7.4 The Impact of Pylorus-Resecting Pancreaticoduodenectomy (PrPD); 7.5 Long-Term Outcomes in PrPD; References; 8: Pancreaticoduodenectomy with Portal Vein Resection; 8.1 Diagnostic Workup; 8.2 Classification of Venous Involvement; 8.3 Technical Aspects of Venous Resections